Johnson & Johnson could announce an agreement as soon as Monday to acquire Texas-based biotechnology company Ollin Biosciences for up to $3.4 billion, in a deal that would strengthen the healthcare group’s position in treatments for serious eye diseases, the Financial Times reported.
Under the terms being discussed, Johnson & Johnson would pay $2.2 billion upfront in cash, with a further $1.2 billion tied to potential milestone payments, the newspaper reported, citing people familiar with the matter.
The proposed acquisition would give Johnson & Johnson access to Ollin’s experimental drug OLN324, which is being developed for diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Both conditions are major causes of vision loss and represent significant treatment markets for pharmaceutical companies.
Register for the next Tekedia Mini-MBA.
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Ollin raised $330 million in June to advance late-stage clinical studies of the drug, positioning OLN324 as its central development asset. The potential transaction would therefore give Johnson & Johnson exposure to a late-stage experimental treatment rather than requiring it to build a similar programme from an earlier stage.
Eye disease treatment offers the company a new growth opportunity.
The proposed deal underscores Johnson & Johnson’s efforts to expand its pharmaceutical pipeline through acquisitions, particularly in areas where experimental treatments could strengthen its position in established medical markets.
Diabetic macular edema develops when diabetes damages blood vessels in the retina, causing fluid to accumulate in the macula and impair central vision. Wet age-related macular degeneration involves abnormal blood vessel growth beneath the retina, which can lead to rapid vision loss if left untreated.
Both conditions require ongoing medical management, creating demand for therapies that can preserve vision and improve treatment outcomes.
OLN324’s late-stage development is key to the potential acquisition’s appeal. Clinical progress can reduce some of the uncertainty associated with early-stage biotechnology investments, although a drug’s commercial prospects remain dependent on clinical results, regulatory approval, and its ability to compete with existing treatments.
The proposed payment structure also indicates how the parties could allocate some of that risk. The $2.2 billion upfront payment would provide immediate value to Ollin’s investors, while the additional $1.2 billion would depend on the achievement of specified milestones. Such arrangements allow an acquirer to link part of the purchase price to future development or commercial progress.
However, the reported terms have not been confirmed by either company, and the milestone conditions have not been disclosed.
The potential Ollin transaction would add to a series of acquisitions through which Johnson & Johnson has sought to strengthen its pharmaceutical business and secure future sources of revenue.
Earlier this year, the company acquired biotechnology firm Firefly Bio for $1 billion in cash as it expanded its cancer drug pipeline. In 2025, it completed its $14.6 billion acquisition of Intra-Cellular Therapies, broadening its presence in treatments for neurological disorders.
The transactions show the company’s willingness to use acquisitions to access specialized drug development programmes and diversify its portfolio across therapeutic areas.
For large pharmaceutical companies, this approach can help address the risk that existing medicines eventually lose market exclusivity or face stronger competition. Acquiring biotechnology companies with promising experimental drugs offers access to potential future products, although the financial returns are not guaranteed.
If completed at the reported valuation, the Ollin acquisition would represent a substantial investment in ophthalmology. However, its success is heavily tied to OLN324’s clinical performance and the commercial opportunity available if the drug secures regulatory approval.
The reported $3.4 billion price tag would also place significant value on a single experimental asset and its development potential. Investors would therefore need to assess the drug’s clinical data, competitive position and eventual revenue prospects against the acquisition cost.
As the reported agreement remains unconfirmed, an announcement would provide greater clarity on the financial terms, development milestones and how Johnson & Johnson intends to integrate Ollin’s programme into its pharmaceutical portfolio.



